Questionable links between doctors and the pharma industry reached their apogee in the U.S. at the start of the millennium, when fierce competition among companies at a time of slowing innovation resulted in the creation of a slew of “me too” drugs, often with little advantage over existing treatment, the Financial Times reports. Report